

3

Docket No. GIR-T100  
Serial No. 09/639,859Remarks

Claims 1-11 were initially pending in the subject application. By way of Preliminary Amendments of October 30, 2000, December 19, 2000, and September 27, 2001, claim 12 was cancelled, claims 2, 3, 6, and 9 were amended, and claims 12-88 were added. In response to a Restriction Requirement dated May 31, 2002, Group II, claims 4, 6-10, 15, and 23-88 were elected without traverse, and new claims 89-95 were added, for examination on June 24, 2002. Claims 94 and 95 have been amended in this application to correct the dependencies of those claims. Thus, claims 4, 6-10, 15, and 23-95 are currently pending and before the examiner for consideration.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicant invites the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2421 NW 41st Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/jaj

Enclosure: Marked-Up Version of Amended Claims

**Marked-Up Version of Amended Claims****Claim 94. (Amended):**

The therapeutic composition or anti-inflammatory medicant according to claim ~~95~~90,  
wherein said peptides, polypeptides, medicants, or proteins are antibiotics.

**Claim 95. (Amended):**

The therapeutic composition or anti-inflammatory medicant according to claim ~~95~~90,  
wherein said peptides, polypeptides, medicants, or proteins are immunosuppressants.